| Cvs Pharmacy #16018 | |
| 3600 S Louise Ave, Sioux Falls, South Dakota 57106 | |
| (605) 254-1100 |
| Name | Cvs Pharmacy #16018 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 3600 S Louise Ave, Sioux Falls, South Dakota 57106 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (605) 254-1100 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.
The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).
Job burnout can strike workers in nearly any field, but a new study finds that doctors are at special risk. Nearly 1 in 2 U.S. physicians report at least one symptom of burnout, with doctors at the front line of care particularly vulnerable, the study found - a significantly higher rate than among the general working population.
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
› Verified 2 days ago
| NPI Number | 1417979162 |
| Organization Name | CVS PHARMACY INC. |
| Doing Business As | CVS PHARMACY #16018 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 3600 S Louise Ave, Sioux Falls, SD 57106 |
| Phone Number | 605-254-1100 |
News Archive
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.
The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).
Job burnout can strike workers in nearly any field, but a new study finds that doctors are at special risk. Nearly 1 in 2 U.S. physicians report at least one symptom of burnout, with doctors at the front line of care particularly vulnerable, the study found - a significantly higher rate than among the general working population.
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
› Verified 2 days ago
News Archive
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.
The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).
Job burnout can strike workers in nearly any field, but a new study finds that doctors are at special risk. Nearly 1 in 2 U.S. physicians report at least one symptom of burnout, with doctors at the front line of care particularly vulnerable, the study found - a significantly higher rate than among the general working population.
BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.
W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.
› Verified 2 days ago
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3703n Cliff Ave, Sioux Falls, South Dakota 57104 Phone: (605) 334-8418 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4930 N Cliff Ave, Sioux Falls, South Dakota 57104 Phone: (605) 332-2858 | |
Cigna Home Delivery Pharmacy Type: Pharmacy Location: 4901 N 4th Ave, Sioux Falls, South Dakota 57104 Phone: (800) 835-3784 | |
Complete Medical Supply Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5107 W 41st St, Sioux Falls, South Dakota 57106 Phone: (605) 275-0270 | |
Partner Medical Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3138 S Minnesota Ave, Sioux Falls, South Dakota 57105 Phone: (605) 275-0083 |